Wall Street analysts were impressed by data showing competitive rates of weight loss for Viking’s therapy, but shares in the ...
The Danish drugmaker’s arch-rival Eli Lilly & Co. has introduced another shot — Zepbound, also known as Mounjaro — that so ...
Despite supply chain issues easing, patients seeking weight-loss drugs like Wegovy and Zepbound are turning to cheaper ...
Reuters on MSN6h
Analysis-Americans hungry for weight-loss drugs grapple with supply and insurance hurdles"Today, we cannot get the 0.25 milligram dose of Wegovy or Zepbound in 10mg, so it really depends on the dose and the day," ...
It isn’t that Wall Street doubts the massive opportunity to treat hundreds of millions of people with obesity worldwide; ...
A trial, targeted at people living with obesity from Britain to Puerto Rico, is the first head-to-head comparison of the ...
The drugmaker hopes to show CagriSema leads to at least 25% weight loss, without increased side effects. Its lead in a ...
Zepbound and Wegovy are both from this class. There were no serious adverse events reported from either trial, she said. (Reporting by Maggie Fick; Editing by Jan Harvey and Susan Fenton) ...
AstraZeneca said on Monday its experimental weight-loss pill, licensed a year ago from China's Eccogene for up to $2 billion, ...
There’s been lots of attention on type 2 diabetes drugs recently, especially since they might also be able to support weight ...
Viking Therapeutics (VKTX) released new clinical trial data on Sunday for its experimental weight-loss drugs, which include a highly anticipated oral pill.
In a deal worth up to $285 million initially for the lead program, Novo Nordisk will gain access to Ascendis’ TransCon ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback